OCTUMI-4: Evaluation of Mirtazapine and Folic Acid for Schizophrenia:A randomised, double-blind, 2x2 factorial trial

Principal research question: Is mirtazapine as add-on therapy to antipsychotic treatment more effective than placebo for treatment of positive and negative symptoms of schizophrenia? Current treatments for schizophrenia, primarily antipsychotic drugs, are not fully effective. There is some evidence that treatment with mirtazapine plus an antipsychotic may be more effective than an antipsychotic alone ((Berk, Ichim & Brook 2001; Joffe et al. 2009; Zoccali et al. 2004)). OCTUMI-4 is designed to evaluate the effects of mirtazapine as add-on therapy to antipsychotic treatment in patients with schizophrenia who are currently experiencing active psychotic symptoms. OCTUMI-4 will be a double-blind placebo controlled randomised trial.